Viralytics raises $4.7m to fund melanoma trial
Tuesday, 20 December, 2011
Viralytics has announced it has raised $4.7 million in a share purchase plan, which has raised the company’s cash reserves to over $8 million.
The fund raising was undertaken to coincide with the commencement of patient enrolment in the company’s US-based phase II melanoma trial.
The issue price of the shares was 30.84c and was based on the five day volume weighted price as of 14 December.
Viraltyics’ (ASX:VLA) share price dropped 5.5% to 34c by mid-afternoon, down from 36c at Monday’s close.
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
